Zai Lab’s Augtyro Receives the NMPA’s Approval to Treat Non-Small-Cell Lung Cancer (NSCLC)
Shots:
- The NMPA has approved Augtyro for treating locally advanced or metastatic ROS1+ NSCLC adults based on the P-I/II (TRIDENT-1) trial
- The P-I/II (TRIDENT-1) study assessed the safety, tolerability, PK & anti-tumor activity of Augtyro in TKI-naïve and TKI-pretreated patients with ROS1+ NSCLC where P-I determined the RP2D
- In the study, 79% of TKI-naïve patients (n=71) achieved 6% CRs & 73% PRs; mDoR was 34.1mos. while 38% of TKI-pretreated patients (n=56) achieved 5% CRs & 32% PRs; mDOR was 14.8mos. In patients with measurable CNS metastases at baseline, 7/8 TKI-naïve & 5/12 TKI-pretreated patients had responses in intracranial lesions
Ref: Zai Lab | Image: Zai Lab
Related News:- Zai Lab and Novocure Report P-III Trial (LUNAR) Results of Tumor Treating Fields Therapy for Metastatic Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
